1 0 4 3 a r t I C l e S Multiple lines of evidence strongly support a genetic basis for autism spectrum disorders (ASD). De novo mutations, originating primarily in the parental germline, are individually rare but their collective risk is substantial and accounts for an estimated 30% of simplex ASD cases 1,2 . Most of the emphasis on identifying high-impact risk variants has focused on establishing burden for likely gene-disruptive (LGD) mutations (nonsense, frameshift or splice-site) 3-5 . High-impact risk genes with primarily de novo missense mutations have been understudied because a much smaller fraction (13%) are thought to be pathogenic when compared to de novo LGD mutations (42%) 1 . Moreover, de novo missense mutations are eight times as common, making it more challenging to prove their statistical relevance. Notwithstanding, a comparison of mutation rates in individuals with ASD and their unaffected siblings reveals that missense mutations contribute to disease risk in as many, if not more, cases than LGD mutations (12% versus 9%, respectively) 1 .
a r t I C l e S In some cases, this may reflect genes with such critical functions that LGD mutations are incompatible with life 1, 6 . In other cases, the mutation's effect on the protein may differ. For example, missense mutations are more likely to have a gain-of-function effect 7 when compared to LGD mutations, which are predominantly loss-of-function. Clustering of missense mutations may highlight important and even previously unknown functional domains, providing insight into ASD pathogenesis and future downstream therapeutic targets. High-confidence ASD risk genes have been successfully identified by searching for mutation recurrence 3, 4, 8, 9 . Given that missense mutations are more common and ~90% of them are thought to be incidental 1 , a much larger sample size is required to prove pathogenicity. We took advantage of the substantial phenotypic and genotypic overlap between ASD, developmental delay and intellectual disability, epilepsy, congenital heart disease and schizophrenia 10 to study the pattern and distribution of de novo missense mutations more broadly. We focused on recurrent site and clustered mutations and tested a larger cohort of affected children to identify pathogenic events and implicate new missense 'hotspot' genes in NDD pathogenesis.
RESULTS

Properties of de novo missense mutations in NDD patients
We began by assessing the rates of de novo missense mutation in cases and controls. We identified a total of 5,807 de novo missense mutations in cases (n = 8,477) and 1,475 such events in controls (n = 2,178) (Supplementary Table 1 ). The fraction of probands with one or more event (50.7%) was significantly greater than the fraction of controls (47.8%; P = 0.016, odds ratio (OR) = 1.12 [1.02-1.24, 95% confidence interval (CI)], two-tailed Fisher's exact test) ( Fig. 1a) . As there were over three times as many cases as controls, we sought to limit the possibility that the signal was driven by rare outliers in cases and thus applied a secondary test, downsampling cases to match the number of controls. This further confirmed a significant increase in the rate of de novo missense mutations in cases (one-tailed empirical P = 9.22 × 10 −4 , OR = 1.12 [1.06-1.19, 95% CI, 1 × 10 6 permutations) ( Fig. 1a) . While the odds ratios for these two tests are nearly identical, the Fisher's exact test is considered more conservative and the hypergeometric distribution generates a wider confidence bound for the odds ratio when compared to that obtained by simulation. Out of 4,227 genes with rare de novo missense mutations in cases, 974 (23.0%) harbored mutations in two or more unrelated cases (Supplementary Table 2 ). In contrast, among controls, 101 out of 1,362 genes (7.4%) were mutated recurrently ( Supplementary Table 3 ). Matching the number of cases and controls, we observed a significant increase in the number of genes among cases with two or more (onetailed empirical P = 0.011, OR = 1.26 [1.10-1.42, 95% CI], 1 × 10 6 permutations) and three or more (one-tailed empirical P = 3.10 × 10 −5 , OR = 3.13 [2.22-4. 03, 95% CI], 1 × 10 6 permutations) de novo missense mutations (Fig. 1b) . The increased recurrence rate is not explained by increased mRNA or protein length, as genes with recurrent mutations in cases were significantly shorter than those with recurrent mutations in controls (mRNA, P = 5.19 × 10 −3 ; protein, P = 1.47 × 10 −3 ; two-tailed Wilcoxon rank-sum tests). Additionally, the total number of genes with mutations was smaller among cases (1, 323 in downsampled cases versus 1,362 in controls), suggesting that mutations in cases are not randomly distributed but rather cluster within fewer genes.
We next compared the severity of de novo missense mutations between cases and controls by assessing the Combined Annotation-Dependent Depletion (CADD) score 11 . The CADD score distribution was significantly positively skewed in cases compared to controls, consistent with an increase in deleteriousness (P = 2.2 × 10 −4 , two-tailed Wilcoxon rank-sum test). Further, at increasing minimum CADD score thresholds, the likelihood that an observed event can be attributed to a case increased ( Fig. 2a) . At a CADD threshold of 28, the likelihood rose dramatically (>1.2 positive likelihood ratio). Notably, mutations in genes with higher levels of recurrence in cases also showed significantly higher CADD scores (P = 5.87 × 10 −29 , F = 45.12, 3 d.f., one-way ANOVA), indicating that recurrence and severity are both valuable markers of missense pathogenicity and that they are highly correlated ( Fig. 2b) .
Genes with recurrent missense mutations
To further assess gene-specific recurrent mutations, we applied a probabilistic model that calculates the expected number of mutations in a gene, based on locus-and base-specific relative substitution rates 12, 13 (see Online Methods). We identified 35 genes that had significantly more de novo missense mutations in cases than expected (false discovery rate < 5%) ( Supplementary Table 2 ). Only two genes, YIF1A and PHKA2, reached significance in controls ( Supplementary  Table 3 ). For 17 of the genes significant in cases, an excess of lossof-function mutations has already been established by copy number variants (CNVs) and LGD mutation (for example, GRIN2B, PTEN and SCN2A) [14] [15] [16] . For 13 of the remaining significant genes, no LGD mutations have been identified in the 24 cohorts studied here or in individuals with NDD in the Online Mendelian Inheritance in Man (OMIM; http://omim.org/) or ClinVar (https://www.ncbi.nlm.nih. gov/clinvar/) databases. While six of these missense-only genes are well known and associated with specific phenotypes (for example, PACS1 and Schuurs-Hoeijmakers syndrome 17 ), the remaining seven warrant follow-up. a r t I C l e S As a set, the 35 genes with excess de novo missense mutations are enriched for aspects of neuronal communication such as postsynaptic membrane potential regulation (6 observed versus 0.17 expected, 35.3-fold enrichment, P adj (adjusted P-value, Bonferroni corrected) = 1.61 × 10 −4 , two-tailed binomial test) and synaptic signaling (8 observed versus 0.7 expected, 11.4-fold enrichment, P adj = 3.30 × 10 −3 , two-tailed binomial test), nervous system development (16 observed versus 3.7 expected, 4.4-fold enrichment, P adj = 1.05 × 10 −3 , two-tailed binomial test) and gene expression regulation (3 observed versus 0.03 expected, >100-fold enrichment, P adj = 2.42 × 10 −2 , two-tailed binomial test). There was also significant enrichment for genes involved in the presynapse (5 of 336 genes; P = 3.74 × 10 −4 , OR = 9.25 [3.40-, 95% CI], one-tailed Fisher's exact test) and postsynaptic density (11 of 1,755 genes; P = 2.17 × 10 −4 , OR = 4.50 [2.26-, 95% CI], one-tailed Fisher's exact test), and targets of FMRP (14 of 842 genes; P = 1.20 × 10 −10 , OR = 14.37 [7.57-, 95% CI], one-tailed Fisher's exact test).
In addition to recurrent mutations within the protein-coding portion of genes, we also assessed amino acids in which two or more de novo missense mutations in unrelated individuals with NDDs have been identified, hereafter referred to as sites. We identified 40 sites in 36 genes, 10 of which have a significant burden of de novo missense mutation, after excluding mutations observed in population controls (minor allele frequency (MAF) > 0.01% in the Exome Sequencing Project (ESP; NHLBI GO ESP Exome Variant Server, Seattle, WA; http://evs.gs.washington.edu/EVS/, August 2016) (n = 6,503) or the Exome Aggregation Consortium 18 (ExAC) database v.0.3 without neuropsychiatric disorders (n = 45,376)) (Supplementary Table 4 ). None of these mutations were observed in unaffected controls in denovo-db v.0.9. Seven sites had more than two recurrent mutations (for example, PACS1 with six mutations at residue 203) and some genes (for example, SCN2A) had more than one recurrently mutated amino acid residue. Sixteen of the amino acid sites involved adjacent mutations in the same codon. Twenty-eight of the 40 sites (36 of 56 mutations) involved CpG dinucleotides, consistent with their known association with hotspots of single-nucleotide variation 19 . Thirty-four sites had average mutation CADD scores of 20 or greater and 17 had a score over 30, indicating that they are in the top 1% of deleterious mutations in the human genome. This observation stands in contrast to the pattern of de novo recurrent missense in controls, where only one of the three sites had a CADD score greater than 20, although the number of events compared is few.
Targeted sequencing of missense mutations
Using single-molecule molecular inversion probes (smMIPs), we targeted 20 of these recurrent sites for sequencing in a large cohort of 17,688 patients with a primary diagnosis of ASD or developmental delay (including intellectual disability; Supplementary Tables 5 and 6). The set included primarily patients with idiopathic NDDs not yet tested by exome sequencing. We also included a set of unaffected siblings and other unaffected individuals as an additional control (n = 3,023). We identified and validated 21 recurrent missense variants at 12 sites in 11 genes among cases ( Fig. 3a-c a r t I C l e S determined due to missing parental DNA. Six of these were de novo missense mutations ( Table 1) : PACS1 p.Arg203 (two mutations), GRIA1 p.Ala636, SCN2A p.Arg937, and SMAD4 p.Ile500 (two mutations). Of note, one of the inherited mutations (PTPN11 p.Gly503) is adjacent to the well-known Noonan syndrome recurrent mutation 20 (PTPN11 p.Ser502) and was transmitted paternally to two children both affected with ASD and intellectual disability. No information on the father's phenotype is currently available. Five genes corresponding to six sites were identified with two or more recurrent missense mutations in the NDD cohort, namely GRIA1 p.Ala636, PACS1 p.Arg203, SCN2A p.Arg379, SCN2A p.Arg937, SMAD4 p.Ile500, and ZNF215 p.Arg473. Phenotypic similarities are present in patients with shared mutations, such as those in ALG13 (Fig. 3b) , where all six individuals with a mutation at residue 107 have both epilepsy and developmental delay even though they were recruited from cohorts with different primary diagnostic criteria. Both individuals with newly found mutations at SMAD4 p.Ile500 have features consistent with Myhre syndrome, including intellectual disability, short stature, facial dysmorphisms and hearing loss 21, 22 (Supplementary Clinical Case Reports).
We also observed rare, potentially disruptive, missense variants in close proximity to the original recurrent site mutations, such as that in SMAD4 (Fig. 3c) , and therefore reexamined our database for regions where multiple de novo missense mutations mapped within 10 amino acids. We designed smMIPs for 17 clustered regions as well as the 20 recurrent sites (in 30 total genes) and sequenced this extended set (~5 kbp of coding sequence) in a subset of the NDD cohort ( Supplementary Tables 5 and 6 ). Combined with targeted sites, we discovered a total of 139 recurrent or clustered missense variants in 137 cases compared to 7 variants in 6 unaffected controls, representing a significant enrichment (P = 1.11 × 10 −4 , OR = 3.93 [1.76-10.89, 95% CI], two-tailed Fisher's exact test) ( Table 2 and Supplementary  Table 7 ). Twelve of the clustered missense mutations in cases were confirmed to be de novo, including events in SATB2 (Fig. 3d) , GRIA1 (Fig. 4a) , SCN2A, KCNQ3, SCN8A, DEAF1 and PPR2R1A (Supplementary Table 8 ).
In addition to new variants at sites in denovo-db v.0.9, targeted sequencing established 14 new sites, although inheritance status for most variants remains unknown. The specific variants at SCN8A p.Arg1617 and STXBP1 p.Arg551 have been seen previously in NDD. While Myhre syndrome has been associated 22 only with residue 500 of SMAD4, in silico predictions suggest that the p.Arg496Cys mutations we identified are also likely to be pathogenic as the residue is highly conserved across species and the amino acid substitution is nonconservative 23 . Detailed phenotypic information on one patient with this mutation indicates characteristics of the syndrome, including intellectual disability, short stature and dysmorphic facial features, suggesting that Myhre syndrome is not only limited to one amino acid 22 . Phenotypic commonalities are also present among individuals with clustered mutations, indicating the functional relevance of protein domains. For example, seven out of eight patients with a mutation in the first DNA binding domain of SATB2 ( Fig. 3d) have facial dysmorphisms and seven out of eight have developmental delay.
De novo missense mutations in GRIA1
We identified a recurrently mutated amino acid in GRIA1 (Fig. 4a) , encoding GluA1, a subunit of AMPA glutamate receptors, which was originally reported in one patient with intellectual disability 24 and another with ASD 14 . Both patients share a de novo G>A mutation resulting in an alanine-to-threonine amino acid replacement at residue 636 (NP_000818.2). Resequencing identified the same variant in three more patients with a primary diagnosis of ASD. One newly a r t I C l e S found mutation was confirmed as de novo; paternal DNA was not available for the other two but the mutation is not present in either of the patients' mothers. Using array comparative genomic hybridization, we found no evidence for large pathogenic CNVs in any of the three patients for whom we had DNA. While this position is a CpG dinucleotide and therefore prone to recurrent mutation, this variant has not been observed in 60,706 individuals studied by ExAC 18 . Moreover, we identified a second de novo missense mutation in close proximity (Fig. 4a ) in a patient with developmental delay. The dearth of variants in healthy controls and the observation of the same recurrent variant in six unrelated patients (three of which were de novo; P = 5.39 × 10 −3 , one-tailed binomial test, genome-wide correction) suggested that the mutation is pathogenic. The mutated site maps to the eighth position (p.Ala636) of a highly conserved nine-amino acid motif, SYTANLAAF (Fig. 4b) , present in the M3 transmembrane domain of all glutamate receptors, which plays a critical role in channel gating 25 . The specific alanine-to-threonine mutation observed in the five patients here has been observed at the functionally equivalent site in other members of the glutamate receptor gene family. It was first identified as a spontaneous mutation in Grid2 in a mouse line at Jackson Laboratories (Lurcher) that results in a constitutively active channel comprised of homomeric GluRδ2 subunits selectively expressed in cerebellar Purkinje neurons 26 . Mice heterozygous for this mutation in the GluRδ2 receptor develop severe ataxia as a consequence of neurotoxicity from excess current flux. Notably, humans with the mutation in GluRδ2 also suffer from ataxia 27 . Engineering of the A>T mutation at the homologous site in the rat isoform of the GluA1 receptor produces a similar constitutively active phenotype with altered kinetic and pharmacological properties [28] [29] [30] .
To confirm constitutive activity or leak current in the human isoform of GRIA1 identified in affected patients, we synthesized cDNA encoding the human wild-type (WT) and mutant (A636T) at basepair position 1906 (G/A). Leak current was measured using whole-cell voltage-clamp recordings of HEK 293 cells heterologously expressing either WT or A636T in the absence of agonist by applying a voltage ramp from −100 mV to +80 mV. GluA1-mediated current was confirmed by application of the AMPA receptor-selective antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX), followed by an additional voltage ramp. Subtracted current in the presence of NBQX revealed a notable constitutive current in A636T-expressing but not WT-expressing cells (Fig. 4d,f) . Consistent with GluA1-mediated current, inward rectification was abolished following channel blockade with NBQX. No changes in current magnitude or shape were seen in cells expressing the WT channel after NBQX application (Fig. 4c,f) . Affected patients with the A636T mutation were heterozygous, indicating that a majority of receptors likely contain WT and A636T receptor subunits. To assess the functional a r t I C l e S phenotype of these heteromeric receptors, we cotransfected equal ratios of WT and A636T DNA and performed the same voltage-ramp recordings (Fig. 4e) . While a noticeable constitutive current was still present, it was smaller than with the homomeric A636T channel, demonstrating that the overall effects of the mutation are mitigated by the presence of the WT subunits (Fig. 4f) . Consistent with the prevalent role of GluA1 homomeric channels in synapse development and synaptic plasticity 31 , phenotypic analysis of four of the individuals with the A636T mutation demonstrated common features ( Supplementary Table 9 ), including mild to moderate intellectual disability (all four individuals) and ASD (three of the four). Three of the four for whom information is available had delayed language development, with two (both with ASD) 
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Current (pA) Figure 5 Proteins with excessive clustering of missense mutations in NDD cases. The pattern of de novo missense mutations in cases with NDDs is contrasted with that of rare missense variants from the 1000 Genomes Project (1KG) and private missense mutations from ExAC excluding those associated with neuropsychiatric diagnoses. Missense mutations are colored by severity (CADD heat map) and recurrent de novo mutations at a specific amino acid position are indicated (triangle). Significance of clustering was calculated based on comparison to ExAC using CLUMP. a r t I C l e S demonstrating persistent difficulties with pronunciation and vocabulary. These two individuals were also noted to have highly similar facial features and were diagnosed with ADHD. Similarly, the individual without ASD was noted to have behavioral dysfunction. Two individuals also had delayed motor development. All four had normal MRIs. Collectively our evidence suggests that this specific missense mutation dictates a common pathological brain development trajectory and supports the idea that specific missense mutations contribute to NDD pathogenesis.
Clustered missense mutations and functional domains
Our sequencing results as well as the GRIA1 analysis strongly suggest that clustered and recurrent missense mutations have the potential to highlight functional protein domains important in NDD pathology. We previously developed a tool, CLUMP 7 , to assess the significance of clustered mutations, and we applied it to an updated version of denovo-db (v.1.2) to identify genes and functional domains for future investigation. Overall, we examined 8,917 de novo missense mutations in cases and calculated raw CLUMP scores for 1,699 proteins containing at least two mutations in cases. We performed case-control analyses comparing the pattern of private alleles in ExAC and separately among European individuals from the 1000 Genomes Project (see Online Methods). Twenty-eight out of 34 genes we initially identified were testable by this approach and 18 of them showed nominally significant clustering of de novo missense mutations (P < 0.05, CLUMP, one-tailed permutation test). Altogether, we identified 200 genes with significant clustering of missense mutations at the protein level ( Supplementary Table 10 ). Once again, this set was significantly associated with aspects of neuronal communication, including regulation of the postsynaptic potential (11 observed versus 1 expected, 11.0-fold enrichment, P adj = 6.93 × 10 −5 , two-tailed binomial test) and synaptic signaling (20 observed versus 4.15 expected, 4.82-fold enrichment, P adj = 8.38 × 10 −5 , two-tailed binomial test), as well as chromatin-mediated maintenance of transcription (4 observed versus 0.1 expected, 40.7-fold enrichment, P adj = 2.96 × 10 −2 , two-tailed binomial test). Many of the genes encoded channel proteins and receptors (for example, GRIA1, GRIN1, GRIN2A, GRIN2B, KCNH1, KCNQ2) and exhibited clustering in or near specific functional domains, such as the transmembrane, pore or voltage sensor domains ( Fig. 5a-d) . Other proteins, such as CTCF, were remarkable in that the clustering pattern of missense mutations in cases highlighted a subset of the C2H2 zinc finger motifs, which were never mutated in controls (Fig. 5e) . These pockets of patient-only missense mutations will be increasingly important in characterizing pathogenic genes and functional domains.
DISCUSSION
The objective of this research study was twofold: define the features of likely disease-causing de novo missense mutations and identify new genes and functional domains relevant to the pathology of NDDs. To increase sample size, we broadly defined NDDs to include not only data from patients with ASD, developmental delay and intellectual disability but also patients with epilepsy and schizophrenia because of the extensive comorbidity of these diagnoses. As expected, both recurrence and severity of missense mutations were critical features. The likelihood of a pathogenic mutation rose significantly when three or more missense mutations were observed in a gene (P = 1.06 × 10 −18 , two-tailed Wilcoxon rank-sum test) and, in particular, when the severity of the missense mutation exceeded a CADD score of 28 (>1.2 positive likelihood ratio). We use these features to identify 35 genes with an excess (false discovery rate < 5%) of de novo missense mutations (Supplementary Table 2) . Targeted sequencing of specific protein-coding regions showed that recurrent and clustered amino acid replacements were more common in cases than controls (P = 1.11 × 10 −4 , OR = 3.93 [1.76-10.89, 95% CI], two-tailed Fisher's exact test). While many of the top-scoring genes were associated with known syndromic and nonsyndromic forms of NDD (for example, SCN2A with ASD 32 , PACS1 with Schuurs-Hoeijmakers syndrome 17 and ALG13 with epilepsy 33 ), seven of these candidates have not been previously reported in ClinVar or OMIM. We also identified 200 genes with patterns of de novo missense mutations that were more clustered in cases than in population controls (Supplementary Table 10) , 79% (n = 157) of which have not yet been associated with an NDD in OMIM or ClinVar databases.
Among the 35 genes with a significant excess of recurrent missense mutations, 37% (n = 13) have not yet been associated with a de novo LGD mutation (for example, COL4A3BP, PPP2R5D), suggesting that LGD events either are not tolerated or are associated with a different diagnostic outcome. In support of this observation, 71% (n = 25) of genes were also recently highlighted as likely pathogenic in an exome sequencing study of 3,287 individuals with developmental delay 15 . Of the 200 genes with significant clustering of missense mutations, 67% (n = 134) did not show any evidence of LGD mutation in NDDs in denovo-db v.1.2, OMIM or ClinVar; 45% (n = 89) have been shown to be loss-of-function intolerant in the ExAC database 18 , suggesting that LGD mutations in them may be genetically lethal (for example, cause embryonic lethality or infertility), although more experiments will be required to make this determination. In many cases, the clustering of de novo mutations highlights protein functional domains (Fig. 5) , such as specific zinc-finger motifs (for example, in CTCF), transmembrane domains (for example, in GRIN1) and voltage sensors and channel pores (for example, in KCNQ2). As the number of exomes increases, these hotspots of pathogenic missense mutation will become more transparent and may be better understood in the context of protein structure. PTPN11, associated with Noonan syndrome 20 , is predicted, for example, to have three clusters by CLUMP, and three-dimensional protein structure analysis revealed that these three clusters define the cleft of the ligand binding site 34 (Supplementary Fig. 1) .
Genes associated with hotspots of missense mutation ( Supplementary Table 10 ) were particularly enriched for presynaptic active zone proteins, FMRP-binding targets and covalent chromatin modification, although not CHD8 target genes. Accumulating evidence supports a link between the development and function of excitatory synapses in NDD and ASD 35 . Consistent with this, we found 35-fold and 11-fold enrichments of genes regulating postsynaptic membrane potential in genes that carried a significant burden and genes with significant clustering of de novo missense events, respectively. While several scaffolding and intracellular signaling proteins have been associated with ASD and disruption of synaptic function, including SH3 and multiple ankyrin repeat domain (SHANK) proteins 36 , synaptic Ras GTPase-activating (SYNGAP) proteins 37 , neurexins 38 , neuroligins 39 and others 35 , a functional mutation in an essential poreforming subunit of an excitatory ionotropic glutamate receptor has not been described to our knowledge.
The fact that five patients with phenotypic similarity were identified with a gain-of-function A636T mutation strongly supports a role for GRIA1 in ASD and related NDDs. This specific de novo missense mutation has been observed before 26 at the homologous position in a highly conserved motif in a different glutamate receptor, GluRδ2. The mutation has a gain-of-function effect, causing constitutive channel opening, neurotoxicity, and degeneration of the cerebellar Purkinje cells in which GluRδ2 is selectively expressed 40 . Both mice and humans with this mutation in GluRδ2 develop ataxia as a direct a r t I C l e S consequence 27 . This mutation in rodent GluA1 (the product of Gria1) has the same effect on channel gating 29, 30 , and here we have replicated this finding in human GluA1. As GluA1 is important in learning and memory 31 , there is a biologically plausible link between this de novo missense mutation in GRIA1 and intellectual disability.
GRIA1 has been demonstrated to play a key role in early synapse development, with GluA1 homomeric channels being inserted into nascent synapses to provide a calcium-permeable, high-conductance channel before being replaced by GluA2-containing channels that mediate long-term synaptic connectivity. Continuing into adulthood, long-term potentiation of excitatory synapses, associated with learning and memory, requires initial insertion of GluA2-absent, calcium-permeable AMPA receptors followed by replacement with GluA2-containing receptors 31 . The developmental and adult function of GluA1 in these contexts likely contributes to the intellectual disability associated with this mutation. Loss-of-function of GluA1 in Gria1 knockout mice leads to impaired synaptic function 41 and behavioral phenotypes, including social behavior deficits and impulsivity 42 , which suggests that bidirectional aberration in excitatory signaling can result in similar ASD and NDD phenotypes. Future studies investigating the impact of the gain-of-function, Lurcher-like A636T mutation in synapse development and function will shed further light on how alterations in excitatory synaptic function contribute to ASD.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
exome data sets and missense mutation annotation. We initially analyzed all de novo missense mutations available from 24 published cohorts 1, 13, 14, 24, 32, 33, of de novo mutations in individuals with NDDs (denovo-db v.0.9; Supplementary  Table 11 ) 64 . The NDD set included 8,477 individuals diagnosed with ASD, developmental delay, intellectual disability, epilepsy, schizophrenia or congenital heart disease (CHD), as well as four cohorts of unaffected controls 1, 47, 65 (n = 2,178) ( Supplementary Table 1 ). Only patients with CHD from Homsy et al. 50 with a secondary diagnosis of NDD were included in this study; we also excluded unaffected siblings of ASD patients as controls if they had a Social Responsiveness Scale (SRS) score ≥60 to remove controls on the autism spectrum 66 . Variants were annotated with SeattleSeq 67 version 138, which provides annotation for all available RefSeq transcripts in GRCh37/hg19. In the case of multiple transcripts, we selected the transcript for which the majority of missense mutations were annotated in both cases and controls. All de novo missense mutations either were previously validated or investigators relied on a high (>95%) validation rate in a subset of mutations to ensure specificity. As some individuals with ASD were assayed as part of multiple cohorts, we took care to remove any duplicate entries. When possible, we compared the global identifier given to the samples that were housed at Rutgers (RUID). Three duplicate entries were found in this manner. For other shared mutations in ASD cohorts, we performed PCR amplification and Sanger sequencing on in-house DNA samples to confirm secondary variants. Five out of six pairs tested-two ASC (Autism Sequencing Consortium)-SSC (Simons Simplex Collection) pairs and three ASC-TASC (The Autism Simplex Collection) pairs-shared a second variant and we therefore assumed them to be duplicates. The presence of uniquely identifying secondary-site mutations was also used to eliminate potential duplicates for globally dispersed samples. We excluded highfrequency mutations (MAF > 0.1%) observed in NHLBI GO ESP Exome Variant Server (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA; http://evs.gs.washington.edu/EVS/, August 2016).
Statistical analyses. Wherever possible, non-parametric tests were used. Data collection and analysis were not performed blind to the conditions of the experiments. Burden was compared between cases and controls for rare (MAF < 0.1% in ESP) de novo missense mutations. Comparisons in rate of mutation and gene recurrence were made using two-tailed Fisher's exact tests. For comparisons of mutation rate and recurrence that depended on identical numbers of cases and controls, we performed 1 million downsamplings and used permutation tests, reporting the empirical P-values. Data distribution was assumed to be normal but was not formally tested. To identify significant enrichments for missense mutations within genes and genic regions, we applied a probabilistic model that incorporates sequence context and human-chimpanzee fixed differences to generate a null model for the distribution of missense variation across the genome and applied a one-tailed binomial test to test for enrichment 13 . For examination of individual codons and specific target regions, we applied the same method but restricted it to the sequence context of the target region and normalized by the gene-specific human-chimpanzee divergence. For all tests we assumed a mutation rate of 1.8 de novo coding variants per generation 12 . Multiple-testing corrections were applied using two procedures based on the analysis type. For significance calculations of whole genes, we used the Benjamini-Hochberg false discovery rate correction based on an estimated 19,000 genes in the human genome 68 and report the q-values for each test. For codon analysis we applied the conservative Bonferroni family-wise error rate correction based on the number of amino acids in the genome (n = 1.1 × 10 7 ) to generate genome-wide significance estimates and report the adjusted P-value (P adj ). Gene ontology enrichment was assessed using PANTHER (database 2017-04-13) for GO biological process annotation and corrected for multiple testing (Bonferroni, reported as P adj ). We also applied a one-tailed Fisher's exact test for testing the enrichment of specific gene sets, including neuronal compartments such as the postsynaptic density 69 and targets of CHD8 (ref. 70 ) and FMRP in brain tissue 71 .
Targeted sequencing. smMIPs 72 were designed with the MIPgen program 73 to capture sequences of interest. To maximize coverage, we designed one smMIP for each strand for each target. We first used smMIPs targeting 24 sites to sequence eight cohorts containing a total of 6,057 cases and 2,854 controls. We also used smMIPs targeting two amino acids thought to be sites (amino acids with de novo missense mutations in two or more unrelated individuals with NDD) but later discovered to be duplicate database entries (TBR1) or present in both the case and her unaffected sister (PDCD11). As clusters of missense mutations have been associated with NDDs 74 , we then designed a set of smMIPs targeting 17 clusters in denovo-db v.0.9 ( Supplementary Table 11 ). These cluster smMIPs, along with the 24 site smMIPs, were used on four more cohorts, containing 5,055 cases and 169 controls. A final set of smMIPs was created that excluded those targeting four sites that had no brain expression (AGER, ZNF215), low CADD scores (ALDH5A1) or high frequency in control populations (DUSP15). This final set, targeting 20 sites and 17 clusters, was used on five new cohorts, containing a total of 6,576 cases (Supplementary Tables 5 and 6) . Across all three designs, this totaled to 17,688 cases and 3,023 controls. The study size was not predetermined but based on the maximum number of samples that could be screened. Reads were aligned using BWA-MEM 75 to GRCh37/hg19. All 146 rare (MAF < 0.01%) variants with CADD score >20 were validated with Sanger sequencing (Supplementary Table 7 ). Patients were initially identified through targeted sequencing in anonymized ASD and developmental delay cohorts. All patients consented to sequencing and recontacting for inheritance testing at the providing laboratory. GRIA1 transfection and patch-clamp recording assays. GRIA1 wild-type and A636T mutant DNA sequences were synthesized (GenScript) and cloned into mammalian expression vectors. Human embryonic kidney (HEK) 293T/17 cells (ATCC CRL-11268), routinely used for transient transfection and electrophysiological recordings as they allow robust heterologous expression, were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum and 1% streptomycin up to a maximum passage number of 15. Cells were validated and certified as mycoplasma free by ATCC (Manassas, VA). For transient transfection, cells were split and plated onto 12-mm glass coverslips (Carolina Scientific) coated with poly-l-lysine (50 ng/µl). Then, 4-6 h later, approximately 0.6 µg of total DNA per coverslip was transfected using the Fugene6 reagent (2 µl per coverslip, Promega). For heteromeric cells, approximately 0.3 µg of WT and A636T were cotransfected. Whole-cell recordings were performed approximately 60 h after transfection using a Multiclamp 700B amplifier (Molecular Devices) with glass micropipettes of resistance 2-5 MΩ. Extracellular solution contained (in mM) 150 NaCl, 2.5 CaCl 2 , 2.5 KCl, 1 MgCl 2 , 10 d-glucose, 10 HEPES, pH to 7.4 with NaOH. Intracellular pipette solution contained (in mM) 140 CsCl, 2 MgCl 2 , 10 HEPES, 10 EGTA, pH to 7.3 with CsOH. Voltage-ramp recordings ranged from −100 mV to 80 mV and spanned 1.8 s. Data were collected with sampling at 10 kHz, and only cells with whole-cell access resistance that remained less than 15 MΩ across recordings were included in analysis. To verify channel expression, a saturating concentration of glutamate (1 mM) was applied with 100 µM CX614, and only cells with detectable current were included. NBQX and CX614 were acquired from Tocris Biosciences. Sample size was chosen based on previous literature and variance observed in ion channel studies of similar nature.
Array comparative genomic hybridization. Array labeling and hybridization was performed as previously described 76 . Briefly, 250 ng of sample DNA was labeled with Cy3 using a NimbleGen labeling kit (Roche). Reference DNA (NA12878) was labeled in a pooled reaction for four arrays with Cy5 using 1 µg of DNA. Hybridization was performed using the Agilent 2x400K array platform using standard reagents, imaged using an Agilent Scanner, and processed using Agilent Feature Extraction. CNV calls were generated using Agilent CytoGenomics 4.03.12 and the ADM2 calling algorithm with default parameters. For samples passing standard Agilent quality control parameters (DLRSD < 0.2), all CNVs over 100 kbp were visually inspected, filtered for known reference sample artifacts, and compared to those seen among 29,085 cases of intellectual disability or developmental delay and 19,584 controls 77 to identify rare CNVs that may contribute to pathogenicity in these cases.
